Disease · MONDO_0006774
habitual spontaneous abortion
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. habitual spontaneous abortion. Diseases, record MONDO_0006774. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006774
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Aborter - recurrent, Abortion, Habitual, Habitual aborter, Habitual aborter - unspecified (disorder), Habitual aborter NOS (disorder), chronic spontaneous abortion, habitual abortion, recurrent abortion (disorder), recurrent miscarriage
- Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets | |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DYDROGESTERONE | CHEMBL1200853 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MISOPROSTOL | CHEMBL606 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOLGRAMOSTIM | CHEMBL2109134 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REGRAMOSTIM | CHEMBL2107881 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| SARGRAMOSTIM | CHEMBL1201670 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| SOYBEAN OIL | CHEMBL1201485 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SERPINC1 | Antithrombin-III | 2 | Antithrombin-III activator | Phase 3 | https://conductscience.org/library/genes/462 | Drugs and targets |
| CSF2RA | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1438 | Drugs and targets |
| CSF2RB | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1439 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 1 | Granulocyte colony stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PGR | Progesterone receptor | 1 | Progesterone receptor agonist | Phase 3 | https://conductscience.org/library/genes/5241 | Drugs and targets |
| PTGER3 | Prostaglandin E2 receptor EP3 subtype | 1 | Prostanoid EP3 receptor agonist | Phase 3 | https://conductscience.org/library/genes/5733 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| TLR7 | Toll-like receptor 7 | 1 | Toll-like receptor 7 antagonist | Unknown | https://conductscience.org/library/genes/51284 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00606905 | Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage | Not applicable | 82 | 2010-08-30 | Miscarriage, Recurrent, Abortion, Habitual | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT02144064 | Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin | Phase 3 | 200 | Recurrent Pregnancy Loss | ASPIRIN, HEPARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04228263 | Hydroxychloroquine and Unexplained Recurrent Miscarriage | Not applicable | 156 | Unexplained Recurrent Miscarriage | ASPIRIN, FOLIC ACID, HYDROXYCHLOROQUINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01068795 | Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome | Not applicable | 144 | Fetal Demise, Fetal Growth Restriction, Preeclampsia, Abruptio Placentae, Thromboembolism | DALTEPARIN SODIUM, ENOXAPARIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01612065 | Optimum Misoprostol Dose Prior to Office Hysteroscopy | Phase 3 | 132 | Infertility, Abnormal Uterine and Vaginal Bleeding, Unspecified, Recurrent Abortion | MISOPROSTOL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03902912 | Effect of Prednisolone Treatment on Uterine Natural Killer Cells | Phase 3 | 84 | Recurrent Miscarriage | PREDNISOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00193674 | Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage | Phase 3 | 71 | Recurrent Miscarriage | DYDROGESTERONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00180778 | Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss | Phase 1/2 | 0 | Antiphospholipid Syndrome | ASPIRIN, HEPARIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| IVIG vs Normal Saline: serious adverse events | 0 of 23 | 0 of 24 | 47 | NCT00606905 |
Source Trial comparisons
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006774
GET https://conductscience.org/api/diseases/v1/MONDO_0006774/drugs